-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the national centralized drug procurement has reached the sixth round.
The impact on the normalization of centralized procurement is not only reflected in the large price cuts of drugs, but also new challenges to the innovation of pharmaceutical companies
.
It needs to be emphasized that the innovation here not only refers to increasing R&D investment in innovative pharmaceutical process technology, but also embodied in digital, integrated, and intelligent research and application
.
Essence Securities recently stated in a research report that since 2019, the country has conducted multiple rounds of centralized drug procurement, and the pharmaceutical manufacturing industry may be reshuffled
.
The agency believes that in the above context, pharmaceutical companies have the ability, willingness, and appeal to upgrade and transform smart manufacturing
.
The transformation of traditional pharmaceutical companies to intelligent manufacturing will help pharmaceutical companies transform from traditional batch production to continuous production mode, improve production efficiency, and shorten product process development cycles; on the other hand, it can also reduce the rate of defective products.
Energy consumption, thereby reducing the overall operating costs of the enterprise
.
In recent years, many pharmaceutical companies have seen the transformation of smart manufacturing in their workshops
.
For example, in Luye Pharma’s sterile injection smart factory, the project introduced and implemented intelligent manufacturing technologies for information management systems such as MES, LIMS, and QMS, aiming at the sterilization requirements of GMP for human errors and cross-contamination in the sterile injection production process , Through the effective connection and integration of pharmaceutical equipment and processes, on the basis of completing multiple aseptic control technology researches such as clean air control, online cleaning, and online sterilization of pharmaceutical equipment, it has realized the manufacturing and inspection of sterile preparation products.
Digital and intelligent management and control have improved the level of product quality management and the safety of clinical medication to a greater extent, and realized the automation, intelligence, and informationization of the production process
.
Yangzijiang Pharmaceutical's intelligent production in workshops, such as the pre-treatment of traditional Chinese medicine at the company’s Longfengtang, is equipped with a dust removal system on the production line to achieve zero dust emission and zero environmental pollution; the workshop’s automation system can seamlessly connect with the logistics system, from the original The whole process of medicinal materials delivery, washing, cutting and drying production line, and then to the storage of pure medicinal materials has been realized; the whole production, the whole process online monitoring, the whole process data collection and video monitoring
.
For another example, in Jiuzhitang's smart factory for solid preparations of traditional Chinese medicine, the application of the new model has significantly changed the company's previous experience of relying on people in pharmaceuticals, greatly improving work efficiency, and product quality more stable
.
Regarding the transformation of pharmaceutical companies' smart manufacturing, the industry believes that under the vigorous promotion of Industry 4.
0, new infrastructure, and smart manufacturing, this transformation direction has become a major trend
.
However, it should be noted that the level of domestic pharmaceutical companies in terms of information investment and other aspects still needs to be improved
.
According to statistics, less than 5% of more than 4,000 pharmaceutical manufacturing companies in the country use computer control.
Most companies still use semi-automatic and manual production technology, which makes the controllability of drugs low, and it is difficult to maintain consistent quality.
.
Analysis of the reasons behind this is mainly due to the particularity of the traditional pharmaceutical industry.
For a long time, there have been phenomena such as small scale, large number, many products, low technical level, and low management level.
The entire industry has been in production, operation and management The level of automation and informatization in other aspects are in a relatively backward state
.
"Although some pharmaceutical companies have begun to explore the communication and data collection of some equipment units, as well as the control of some batch processes with the help of equipment suppliers, they are mostly partial and fail to truly realize the pharmaceutical production process.
Automated batch control and manufacturing execution
.
" Generally speaking, although the direction of intelligent manufacturing of pharmaceutical companies has been set, pharmaceutical companies have achieved "intelligent integration" in drug production and the entire production chain.
There are still many difficulties to go through
.
The impact on the normalization of centralized procurement is not only reflected in the large price cuts of drugs, but also new challenges to the innovation of pharmaceutical companies
.
It needs to be emphasized that the innovation here not only refers to increasing R&D investment in innovative pharmaceutical process technology, but also embodied in digital, integrated, and intelligent research and application
.
Essence Securities recently stated in a research report that since 2019, the country has conducted multiple rounds of centralized drug procurement, and the pharmaceutical manufacturing industry may be reshuffled
.
The agency believes that in the above context, pharmaceutical companies have the ability, willingness, and appeal to upgrade and transform smart manufacturing
.
The transformation of traditional pharmaceutical companies to intelligent manufacturing will help pharmaceutical companies transform from traditional batch production to continuous production mode, improve production efficiency, and shorten product process development cycles; on the other hand, it can also reduce the rate of defective products.
Energy consumption, thereby reducing the overall operating costs of the enterprise
.
In recent years, many pharmaceutical companies have seen the transformation of smart manufacturing in their workshops
.
For example, in Luye Pharma’s sterile injection smart factory, the project introduced and implemented intelligent manufacturing technologies for information management systems such as MES, LIMS, and QMS, aiming at the sterilization requirements of GMP for human errors and cross-contamination in the sterile injection production process , Through the effective connection and integration of pharmaceutical equipment and processes, on the basis of completing multiple aseptic control technology researches such as clean air control, online cleaning, and online sterilization of pharmaceutical equipment, it has realized the manufacturing and inspection of sterile preparation products.
Digital and intelligent management and control have improved the level of product quality management and the safety of clinical medication to a greater extent, and realized the automation, intelligence, and informationization of the production process
.
Yangzijiang Pharmaceutical's intelligent production in workshops, such as the pre-treatment of traditional Chinese medicine at the company’s Longfengtang, is equipped with a dust removal system on the production line to achieve zero dust emission and zero environmental pollution; the workshop’s automation system can seamlessly connect with the logistics system, from the original The whole process of medicinal materials delivery, washing, cutting and drying production line, and then to the storage of pure medicinal materials has been realized; the whole production, the whole process online monitoring, the whole process data collection and video monitoring
.
For another example, in Jiuzhitang's smart factory for solid preparations of traditional Chinese medicine, the application of the new model has significantly changed the company's previous experience of relying on people in pharmaceuticals, greatly improving work efficiency, and product quality more stable
.
Regarding the transformation of pharmaceutical companies' smart manufacturing, the industry believes that under the vigorous promotion of Industry 4.
0, new infrastructure, and smart manufacturing, this transformation direction has become a major trend
.
However, it should be noted that the level of domestic pharmaceutical companies in terms of information investment and other aspects still needs to be improved
.
According to statistics, less than 5% of more than 4,000 pharmaceutical manufacturing companies in the country use computer control.
Most companies still use semi-automatic and manual production technology, which makes the controllability of drugs low, and it is difficult to maintain consistent quality.
.
Analysis of the reasons behind this is mainly due to the particularity of the traditional pharmaceutical industry.
For a long time, there have been phenomena such as small scale, large number, many products, low technical level, and low management level.
The entire industry has been in production, operation and management The level of automation and informatization in other aspects are in a relatively backward state
.
"Although some pharmaceutical companies have begun to explore the communication and data collection of some equipment units, as well as the control of some batch processes with the help of equipment suppliers, they are mostly partial and fail to truly realize the pharmaceutical production process.
Automated batch control and manufacturing execution
.
" Generally speaking, although the direction of intelligent manufacturing of pharmaceutical companies has been set, pharmaceutical companies have achieved "intelligent integration" in drug production and the entire production chain.
There are still many difficulties to go through
.
